3-oxazolo[4,5-c]pyridin-2-yl-5-[1-(4-piperidyl)pyrazol-4-yl]pyridin-2-amine | 1146945-04-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-oxazolo[4,5-c]pyridin-2-yl-5-[1-(4-piperidyl)pyrazol-4-yl]pyridin-2-amine
• 英文别名: 3-Oxazolo[4,5-c]pyridin-2-yl-5-[1-(4-piperidinyl)-1h-pyrazol-4-yl]-2-pyridinamine；3-([1,3]oxazolo[4,5-c]pyridin-2-yl)-5-(1-piperidin-4-ylpyrazol-4-yl)pyridin-2-amine
• CAS: 1146945-04-1
• 化学式: C₁₉H₁₉N₇O
• 分子量: 361.406
• InChiKey: RQNPPYUCHLXACQ-UHFFFAOYSA-N

物化性质

• 沸点：
  612.7±55.0 °C(Predicted)
• 密度：
  1.54±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  108
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  methanolic ammonia 、 4-[4-(4,4,5,5-四甲基-1,3,2-二氧杂环戊硼烷-2-基)-1H-吡唑-1-基]哌啶-1-甲酸叔丁酯 、 5-bromo-3-oxazolo[4,5-c]pyridin-2-yl-pyridin-2-amine 生成 3-oxazolo[4,5-c]pyridin-2-yl-5-[1-(4-piperidyl)pyrazol-4-yl]pyridin-2-amine
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• PYRIDINE AND PYRAZINE DERIVATIVES - 083
  申请人：Barlaam Bernard Christophe

  公开号：US20090118305A1

  公开（公告）日：2009-05-07

  The invention concerns pyridine and pyrazine derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of W, G 1 , G 2 , G 3 , G 4 , J, Ring A, n and R 3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.

  本发明涉及式I的吡啶和吡嗪衍生物 或其药用可接受的盐，其中W、G 1 、G 2 、G 3 、G 4 、J、环A、n和R 3 各自具有如前文描述中定义的任何含义；它们的制备过程，包含它们的药物组合物以及它们在制造用于治疗细胞增殖性障碍的药物中的应用。
• PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DYRK-RELATED DISEASES, CONTAINING PYRIDINE-BASED COMPOUND AS ACTIVE INGREDIENT
  申请人：Korea Research Institute of Bioscience and Biotechnology

  公开号：EP3542797A1

  公开（公告）日：2019-09-25

  The present invention relates to a pharmaceutical composition the prevention or treatment of DYRK-related diseases containing a pyridine-based compound as an active ingredient, a pyridine-based compound of the present invention which is used as an active ingredient of the pharmaceutical composition inhibits the activity of DYRK1A with very high efficacy and selectivity, thereby can be used effectively in the prevention or treatment of DYRK-related diseases, such as Down syndrome, degenerative brain diseases, cancer, and metabolic diseases.

  本发明涉及一种预防或治疗 DYRK 相关疾病的药物组合物，该药物组合物含有吡啶类化合物作为活性成分，本发明的吡啶类化合物作为药物组合物的活性成分，能够以极高的效力和选择性抑制 DYRK1A 的活性，从而可有效用于预防或治疗 DYRK 相关疾病，如唐氏综合征、退行性脑疾病、癌症和代谢性疾病。
• Pharmaceutical composition for preventing or treating DYRK-related diseases, containing pyridine-based compound as active ingredient
  申请人：KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

  公开号：US10765669B2

  公开（公告）日：2020-09-08

  The present invention relates to a pharmaceutical composition the prevention or treatment of DYRK-related diseases containing a pyridine-based compound as an active ingredient, a pyridine-based compound of the present invention which is used as an active ingredient of the pharmaceutical composition inhibits the activity of DYRK1A with very high efficacy and selectivity, thereby can be used effectively in the prevention or treatment of DYRK-related diseases, such as Down syndrome, degenerative brain diseases, cancer, and metabolic diseases.

  本发明涉及一种预防或治疗 DYRK 相关疾病的药物组合物，该药物组合物含有吡啶类化合物作为活性成分，本发明的吡啶类化合物作为药物组合物的活性成分，能够以极高的效力和选择性抑制 DYRK1A 的活性，从而可有效用于预防或治疗 DYRK 相关疾病，如唐氏综合征、退行性脑疾病、癌症和代谢性疾病。
• PYRIDINE AND PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF CELL PROLIFERATIVE DISORDERS
  申请人：AstraZeneca AB

  公开号：EP2215085B1

  公开（公告）日：2011-09-07
• US8017611B2
  申请人：——

  公开号：US8017611B2

  公开（公告）日：2011-09-13